1. Introduction {#sec1}
===============

The prognosis of patients with hepatocellular carcinoma (HCC) depends upon both tumor factors and liver factors \[[@B1]\]. The tumor factors include the maximum tumor diameter (MTD), number of tumors, presence of macroscopic (clinically evident) portal vein thrombosis (PVT), and blood levels of alpha-fetoprotein (AFP). The presence of PVT may be the most important tumor factor, as it reflects tumor aggressiveness (migration, invasion, and potential for metastasis), limits the options for curative resection or transplantation, and can also worsen residual liver function. It is thought that up to 45% of HCC patients have some form of macroscopic PVT \[[@B2a]--[@B4]\] and may be gross or macroscopic as shown on CT or MRI scan or microscopic as evidenced only on pathology. It is poorly understood, with few biological models and little understanding of its causes. However, predisposing factors include increased MTD, with increased levels of the HCC plasma tumor markers des-gamma carboxyprothrombin (DCP) and AFP, decreased serum albumin, and elevated platelet counts \[[@B6]--[@B11]\]. The current study in a large HCC cohort confirms the increased percent of PVT with increasing MTD, as well as with increasing multifocality and AFP. Furthermore, we found that PVT occurred in 13.7% of small HCCs \<5cm, but in 56.4% of large HCCs \>10cm.

2. Methods {#sec2}
==========

2.1. Patient Data {#sec2.1}
-----------------

We analyzed a database of 1773 prospectively accrued HCC patients who had full baseline tumor parameter data, including CT scan information on HCC size, number of tumor nodules, and presence or absence of PVT and plasma AFP levels; complete blood count; routine blood liver function tests (total bilirubin, GGTP, ALKP, albumin, and transaminases); and patient demographics. Diagnosis was made either via tumor biopsy or according to international guidelines. Of these patients, 1029 had low AFP levels (≤100 IU/ml) and are the subject of this study. Database management conformed to legislation on privacy and this study conforms to the ethical guidelines of the Declaration of Helsinki and approval for this retrospective study on deidentified HCC patients was obtained by the Institutional Review Board.

2.2. Statistical Analysis {#sec2.2}
-------------------------

Mean and SD for continuous variables and relative frequency for categorical variables were used as indices of centrality and dispersion of the distribution. For categorical variables, the Chi-square and z test for proportions were used. The Wilcoxon rank-sum (Mann--Whitney) test was to test the difference between two categories and the Kruskal-Wallis rank test to test the difference among categories.

Logistic regression model was to evaluate the associations between PVT (No/Yes) on single variables examined.

Final multiple linear or logistic regression models were obtained with the backward stepwise method and the variables that showed associations with p\<0.10 were left in the models.

When testing the null hypothesis of no association, the probability level of *α* error, two tailed, was 0.05. All the statistical computations were made using STATA 12.1 Statistical Software (StataCorp), 2014, release 12 (College Station, TX).

3. Results {#sec3}
==========

3.1. PVT in Tumor Size (MTD) Groups {#sec3.1}
-----------------------------------

Patients were initially analyzed according to PVT status in different tumor size (MTD) groups ([Table 1](#tab1){ref-type="table"}). There was a large percent increase in PVT positive patients with increase in MTD, 13.7% for small tumors, 33.9% for intermediate tumors, and 56.4% for very large tumors. For small and intermediate size tumor patients, there were more Child-Pugh score A patients without PVT. However, the prevalence of cirrhosis was not different across MTD groups, nor were there differences in total serum bilirubin values. Albumin values were lower in the patients with PVT, but significant only for the small tumor groups. Patients with PVT had a small but significant increase in MTD, in the small and intermediate size tumor groups compared to patients without PVT. However, the AFP levels were significantly higher in the PVT positive patients, for all 3 tumor size groups, as was tumor multifocality. Thus, on the whole, patients with PVT had larger and more multifocal tumors with higher AFP values, yet similar bilirubin levels, across the tumor size groups.

3.2. PVT-Associated Parameters {#sec3.2}
------------------------------

The parameters that were associated with presence of PVT were next examined. A logistic regression model of PVT showed significance for several single parameters as continuous variables ([Table 2(A)](#tab2){ref-type="table"}), but when all parameters were considered together, there was significance in the final model ([Table 2(B)](#tab2){ref-type="table"}) for tumor multifocality, MTD, AFP, ALKP, and albumin. Two of these parameters versus PVT values are shown graphically in [Figure 1](#fig1){ref-type="fig"}, which shows significant increases in percent PVT, in relation to increase of both MTD and AFP. However, even in the highest AFP categories, less than r50% of patients had PVT ([Figure 2](#fig2){ref-type="fig"}).

A logistic regression model of PVT was then performed for the variables of MTD (large or small), AFP (high or low), and tumor multifocality versus unifocality, considered singularly ([Table 3(A)](#tab3){ref-type="table"}) or together ([Table 3(B)](#tab3){ref-type="table"}), as these were the 3 parameters with highest odds ratio (OR) in [Table 2](#tab2){ref-type="table"}. High ORs were found for the high values of each of the 3 parameters, whether considered singularly or together. However, when we combined all 3 parameters of MTD \>5cm plus tumor multifocality plus AFP \>100 IU/ml, an OR of 17.9 was obtained ([Table 3(C)](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

Clinical macroscopic PVT is typically diagnosed as obstruction and expansion of the portal vein on CT or MRI scan \[[@B12]--[@B14]\] or by contrast-enhanced ultrasonography \[[@B15]\]. It is associated with several serum changes, such as the des-gamma-carboxy-prothrombin/vitamin K pathway \[[@B16]--[@B23]\] and is a well-recognized predictor of poor survival in HCC patients \[[@B1], [@B4]--[@B7], [@B24]--[@B26]\]. It is typically diagnosed radiologically \[[@B13]--[@B15]\] and although pathological confirmation often requires examination of resected or transplantation specimens, percutaneous biopsy material can also be used \[[@B27], [@B28]\]. Despite this, some factors have been associated with discriminate better survival among patients with PVT. These include serum albumin levels \[[@B9]\], C-reactive protein \[[@B11]\], and AFP levels \[[@B30]\] and some subsets of patients have been identified as having better prognosis \[[@B24], [@B25], [@B31], [@B32]\]. The causes of increased death in HCC patients with PVT include worsened residual liver function and the presence of tumor cells in the vein as a pathway to systemic spread of tumor and distant metastasis.

The mechanisms involved in the pathogenesis of PVT include disruption of the tumor matrix, migration and invasion of the tumor cells, systemic inflammation \[[@B33]\], and DCP \[[@B16]--[@B19]\]. AFP levels are typically elevated in HCC patients with PVT, but whether they are cause or consequence is unclear.

Treatment of HCC patients with PVT is controversial \[[@B4]\] with more than usual complications and some limited survival benefit \[[@B34], [@B35]\]. Recently, radioembolization has emerged as a safer therapy \[[@B36], [@B37]\], but its effects on survival have yet to be proved. However, some evidence suggests that chemoembolization may also be useful in the presence of PVT \[[@B38], [@B39]\]. Furthermore, Sorafenib has been found to be a safe treatment in this setting \[[@B43]\] and may be as effective as radioembolization. In additional, multiple different radiation modalities have been evaluated in the presence of PVT, with few differences between them \[[@B44]\].

A major finding in this analysis was the increase in % of patients with PVT as MTD increased (Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). We considered 2 possible explanations for this. One is that the same factors that induce tumor growth, such as stem cells or growth factors, also enhance tumor invasion and thus MTD. Alternatively, there might be some change in HCC biology beyond a certain size that is associated with more aggressive features. [Table 1](#tab1){ref-type="table"} shows that the proportion of very large MTD tumors with and without PVT is similar. Furthermore, within this category, average MTD is almost identical. This suggests that it is not tumor size per se. Perhaps there are 2 different growth pathways, one associated with PVT and the other not. This could explain why large tumors are well represented in the PVT positive and negative groups ([Table 1](#tab1){ref-type="table"}). The same [Table 1](#tab1){ref-type="table"} also shows that both tumor multifocality and average AFP values are always significantly higher in every MTD category that has PVT patients compared to each PVT negative category, suggesting that the tumors are more aggressive in the PVT patients, whether they are larger or not. However, even in the highest AFP groups, less than 50% of the patients were PVT positive, as shown in [Figure 2](#fig2){ref-type="fig"}. Other reports have found elevated bilirubin levels in PVT patients, but our data do not really show this. Thus, the patients with PVT in this cohort have aggressive HCCs which did not destroy sufficient liver parenchyma to cause liver failure. PVT is generally classified as macroscopic or microscopic \[[@B4]\]. The current study was based on clinical/nonsurgical evidence (macroscopic) for PVT. Thus, a proportion of our patients classed as PVT negative macroscopically could still be PVT positive microscopically. It has also been reported that PVT seems to occur at a very early stage of HCC evolution \[[@B40]\]. These findings support the idea of 2 possible HCC developmental pathways, namely, HCCs with and without macroscopic PVT. Factors other than MTD and AFP must also be involved in the development of PVT.
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###### 

Comparisons amongst HCC patients between portal vein thrombosis groups, in single MTD categories.

                                 MTD\<5.0 (cm)                        5.0≤MTD≤10.0 (cm)                      MTD\>10.0 (cm)                                                    
  ------------------------------ ------------------ ----------------- ------------------- ------------------ ----------------- ------------ ---------------- ----------------- ------------
                                                                                                                                                                                
  Sex (M) (%)                    145 (79.32)        88 (78.57)        0.86^∧^             319 (82.22)        164 (82.41)       0.95^∧^      72 (85.71)       96 (88.07)        0.63^∧^
  Age (yr)                       61.55±11.04        61.59±11.53       0.98                63.86±10.95        61.24±11.88       0.005        63.89±12.52      60.69±13.68       0.08
  Cigarettes smoke (%)           159 (44.04)        32 (42.11)        0.76^∧^             129 (60.85)        79 (56.03)        0.37^∧^      26 (55.32)       32 (57.14)        0.85^∧^
  Alcohol (%)                    63 (17.65)         8 (11.11)         0.17^∧^             27 (13.85)         25 (18.12)        0.29^∧^      7 (20.00)        7 (12.07)         0.30^∧^
  Child-Pugh (B&C)                                                    0.01 ^∧^                                                 \<0.001^∧^                                      0.47 ^∧^
   A                             217 (39.19)        18 (22.22)                            138 (44.23)        44 (26.04)                     26 (35.14)       23 (26.44)         
   B                             212 (38.27)        41 (50.62)                            118 (37.82)        70 (41.42)                     28 (37.84)       39 (44.83)         
   C                             125 (22.56)        22 (27.16)                            56 (17.95)         55 (32.54)                     20 (27.03)       25 (28.74)         
  Cirrhosis (%)                  542 (79.47)        88 (87.13)        0.07 ^∧^            301 (77.98)        168 (85.71)       0.03^∧^      62 (73.81)       81 (77.88)        0.51 ^∧^
  Albumin (g/dL)                 3.15±0.76          2.95±0.76         0.02                3.11±0.75          2.97±0.71         0.07         3.04±0.74        3.00±0.63         0.60
  GGTP (U/L)                     148.07±186.14      143.42±134.30     0.41                147.47±153.36      210.61±206.48     0.0003       186.06±153.04    213.74±175.12     0.34
  AST (U/L)                      118.06±226.07      102.20±92.59      0.86                100.88±121.40      114.37±105.87     0.02         146.35±425.67    114.46±112.63     0.07
  ALKP (U/L)                     190.97±216.09      191.34±168.76     0.40                193.97±139.92      279.19±313.31     0.02         232.77±149.04    268.86±241.38     0.96
  Bilirubin (mg/dL)              2.41±3.45          2.52±3.41         0.67                2.27±3.67          3.60±5.44         0.009        1.96±3.06        2.58±3.61         0.22
  Platelet counts (10^3^/*μ*L)   139.16±85.58       141.80±90.29      0.92                161.86±89.36       180.04±108.38     0.10         226.94±141.19    227.79±127.74     0.63
  AFP (IU/mL)                    1774.84±13163.19   2722.60±8062.90   \<0.0001            3504.43±18586.15   10976.9±54278.4   0.0007       9395.0±29325.7   18393.3±55766.2   0.02
  MTD (cm)                       2.91±1.01          3.13±0.94         0.03                7.00±1.73          7.47±1.66         0.0004       14.29±3.56       14.24±3.17        0.91
  Nodules number (%)                                                  0.002 ^∧^                                                \<0.001^∧^                                      \<0.001^∧^
   Unifocal                      507 (72.53)        62 (57.94)                            271 (70.76)        98 (50.52)                     67 (79.76)       55 (55.00)         
   Multifocality (≥2)            192 (27.47)        45 (42.06)                            112 (29.24)        96 (49.48)                     17 (20.24)       45 (45.00)         
                                                                                                                                                                                

*∗* All values: means ± standard deviation as continuous; Frequencies and percentage (%) as categorical.

^*ψ*^ Wilcoxon rank-sum (Mann--Whitney) test; ^∧^ Chi-square test.

GGTP, gamma glutamyl transpeptidase; ALKP, alkaline phosphatase; AFP, alpha-fetoprotein; MTD, maximum tumor diameter; PVT, portal vein thrombosis.

###### 

Logistic regression model of PVT *(No/Yes)*, on single variables **(A)**. Final multiple logistic regression model in stepwise method of PVT *(No/Yes)*, on all variables included together in the model **(B)**. All models in total cohort.

  Parameter *∗*                  OR      se(OR)   p-value   95% C.I.
  ------------------------------ ------- -------- --------- ------------------
  (**A**)                                                    
  Platelet counts (10^3^/*μ*L)   1.002   0.001    0.003     1.001 to 1.004
  Hemoglobin (g/dL)              0.899   0.034    0.005     0.835 to 0.969
  GGTP (U/L)                     1.001   0.0004   0.006     1.0003 to 1.0021
  ALKP (U/L)                     1.001   0.0004   0.002     1.0004 to 1.0019
  Total Bilirubin (mg/dL)        1.042   0.021    0.04      1.002 to 1.084
  Albumin (g/dL)                 0.711   0.080    0.002     0.571 to 0.887
  AFP (IU/mL)                                                
   ≤100 *\[Ref. category\]*      1                           
   \>100                         2.091   0.354    \<0.001   1.500 to 2.913
  MTD (cm)                       1.178   0.027    \<0.001   1.127 to 1.231
  Tumor Nodule \#                1.714   0.284    0.001     1.238 to 2.372
  Cirrhosis (yes)                1.388   0.303    0.13      0.905 to 2.130
                                                            
  (**B**)                                                    
  ALKP (U/L)                     1.001   0.0004   0.02      1.0001 to 1.0017
  Albumin (g/dL)                 0.758   0.093    0.02      0.595 to 0.965
  AFP (IU/mL)                                                
   ≤100 *\[Ref. category\]*      1                           
   \>100                         1.632   0.297    0.007     1.143 to 2.331
  MTD (cm)                       1.166   0.027    \<0.001   1.114 to 1.219
  Tumor Nodule \#                1.558   0.281    0.01      1.094 to 2.219

*∗* All variables included in the model were considered as continuous, except the AFP which was considered as categorical.

OR, odds ratio; se(OR), standard error of odds ratio; GGTP, gamma glutamyl transpeptidase; ALKP, alkaline phosphatase; AFP, alpha-fetoprotein; MTD, maximum tumor diameter; PVT, portal vein thrombosis.

###### 

Logistic regression model of PVT (*No/Yes*), on single variables (**A**), all as categories. Final multiple logistic regression model in stepwise method of PVT (*No/Yes*), on all variables as categories, included together in the model (**B**). Combination of MTD (\<5.0/≥5.0), focality (Unifocality/Multifocality), and AFP (≤100/\>100) (**C**).

  Parameter                                              OR      se(OR)   p-value   95% C.I.
  ------------------------------------------------------ ------- -------- --------- ----------------
  (**A**)                                                                            
                                                                                    
  MTD (cm)                                                                           
   \<5.0 *\[Ref. category\]*                             1                           
   ≥5.0                                                  3.97    0.53     \<0.001   3.05 to 5.17
                                                                                    
  Tumor Nodule \#                                                                    
   Unifocality (n=1) *\[Ref. category\]*                 1                           
   Multifocality (n≥2)                                   2.43    0.31     \<0.001   1.90 to 3.11
                                                                                    
  AFP (IU/mL)                                                                        
   ≤100 *\[Ref. category\]*                              1                           
   \>100                                                 2.55    0.32     \<0.001   2.00 to 3.25
                                                                                    
  (**B**)                                                                            
                                                                                    
  MTD (cm)                                                                           
   \<5.0 *\[Ref. category\]*                             1                           
   ≥5.0                                                  3.49    0.48     \<0.001   2.66 to 4.57
  Tumor Nodule \#                                                                    
   Unifocality (n=1) *\[Ref. category\]*                 1                           
   Multifocality (n≥2)                                   2.22    0.29     \<0.001   1.71 to 2.88
  AFP (IU/mL)                                                                        
   ≤100 *\[Ref. category\]*                              1                           
   \>100                                                 2.05    0.27     \<0.001   1.58 to 2.65
                                                                                    
  (**C**)                                                                            
                                                                                    
  Combination of: MTD, Focality, and AFP                                             
                                                                                    
  MTD\<5.0 & Unifocality & AFP≤100 *\[Ref. category\]*   1                           
  MTD\<5.0 & Unifocality & AFP\>100                      2.80    0.82     \<0.001   1.57 to 4.99
  MTD\<5.0 & Multifocality & AFP≤100                     2.17    0.71     0.02      1.15 to 4.11
  MTD\<5.0 & Multifocality & AFP\>100                    6.93    2.31     \<0.001   3.60 to 13.31
  MTD≥5.0 & Unifocality & AFP≤100                        4.68    1.20     \<0.001   2.83 to 7.73
  MTD≥5.0 & Unifocality & AFP\>100                       7.48    1.92     \<0.001   4.52 to 12.38
  MTD≥5.0 & Multifocality & AFP≤100                      9.50    2.76     \<0.001   5.37 to 16.80
  MTD≥5.0 & Multifocality & AFP\>100                     17.94   4.80     \<0.001   10.62 to 30.30

OR, odds ratio; se(OR), standard error of odds ratio; PVT, portal vein thrombosis; MTD, maximum tumor diameter; AFP, alpha-fetoprotein.
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